Research Progress on the Effect of Sodium-glucose Cotransporter 2 Inhibitors on Iron Metabolism in Patients With Heart Failure
10.3969/j.issn.1000-3614.2025.11.012
- VernacularTitle:钠-葡萄糖共转运蛋白2抑制剂影响心力衰竭患者铁代谢的研究进展
- Author:
Xiaosheng LUO
1
;
Juan LEI
;
Zequan ZHENG
;
Guifu WU
Author Information
1. 中山大学附属第八医院 心内科,深圳 518000
- Publication Type:Journal Article
- Keywords:
sodium-glucose cotransporter 2 inhibitor;
heart failure;
iron;
intravenous iron;
ferroptosis
- From:
Chinese Circulation Journal
2025;40(11):1129-1133
- CountryChina
- Language:Chinese
-
Abstract:
Iron deficiency and anemia are common and are associated with poor prognosis in patients with heart failure.Previous studies have found that oral iron supplementation cannot improve quality of life and activity tolerance in patients with heart failure.In recent years,a large number of studies have demonstrated that sodium-glucose cotransporter 2 inhibitor(SGLT2i)can improve the prognosis of patients with heart failure.Researchers have found that they can stimulate erythropoietin secretion,inhibit sympathetic overactivation,inhibit inflammatory response,improve iron absorption and utilization,and inhibit ferroptosis.This article summerizes the effect of SGLT2i on iron metabolism in patients with heart failure,so as to explore possible ways to improve iron deficiency and anemia in patients with heart failure.
